We told you to watch July 24. The FDA hit its own deadline for once: on July 24, 2026, the agency approved Simtriyo (centanafadine), Otsuka’s once-daily extended-release capsule for ADHD — the first norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI) ever cleared for the condition. Otsuka and the FDA didn’t make a public announcement until three days later, which is its own small lesson in why “the PDUFA date” and “the news you actually hear about it” aren’t the same day.

If you read our March breakdown of the centanafadine Phase 3 data, the mechanism story is already familiar: one pill, three neurotransmitter systems, a genuinely new pharmacological approach for the first time in two decades. What’s new now is the stuff that wasn’t knowable back in March — actual dosing, actual side effect rates, and a safety label that complicates the “low abuse potential” pitch more than we expected.

TL;DR for ADHD Brains

Aspect	Details
What happened	FDA approved Simtriyo (centanafadine) on July 24, 2026
What it is	First NDSRI (norepinephrine + dopamine + serotonin reuptake inhibitor) approved for ADHD
Who it’s for	Adults and kids 6+ weighing at least 20kg
Dosing	Adults: 210mg once daily. Adolescents: 280mg once daily. Kids: weight-based, set by prescriber
Available in pharmacies?	Not yet — still needs DEA scheduling, expected later in 2026
Abuse potential	Lower than stimulants in trials, but still carries a boxed warning for abuse/misuse

One-sentence verdict: Simtriyo is real, approved, and genuinely new — but “available” and “risk-free” are both further off than the March headlines implied.

Best for: People who’ve been tracking this since the priority review and want the actual numbers instead of trial-phase optimism Skip if: You need medication now — this isn’t prescribable yet

What Actually Got Approved

Here’s the part that matters if you skipped the mechanism deep-dive in March: Simtriyo is indicated for ADHD in adults and pediatric patients 6 years and older who weigh at least 20kg. Not recommended below that weight or age — the FDA was explicit about that cutoff.

It’s a once-daily extended-release capsule, taken in the morning. If swallowing capsules whole is a problem (a real issue for a lot of kids and some adults), it can be opened and sprinkled over applesauce, yogurt, or orange juice instead. Small detail, but it’s the kind of thing that determines whether a med actually gets taken.

Dosing, per Understood.org’s coverage of the approval:

• Adults: 210mg once daily
• Adolescents (13-17): 280mg once daily
• Children (6-12): dose set by the prescriber based on the child’s weight

No titration schedule climbing toward some ceiling dose that took months to reach — this isn’t the slow-build atomoxetine experience. That’s a meaningfully different rollout than what a lot of non-stimulant switchers are used to.

The Phase 3 Data, Now With an Actual Approval Attached

We covered the trial design in March. Short version of what carried it across the finish line: four randomized, double-blind, placebo-controlled Phase 3 trials across children, adolescents, and adults, all hitting statistically significant improvement over placebo.

Adults were measured on the Adult ADHD Investigator Symptom Rating Scale (AISRS). Kids and teens were measured on the ADHD-RS-5. In both populations, separation from placebo showed up as early as Week 1 and held through the six-week treatment window. That’s the number worth sitting with if you’ve been burned by non-stimulants that take a month to do anything: this isn’t atomoxetine’s slow ramp. It behaves more like a fast-onset option that happens to not be a stimulant.

What Are the Side Effects of Simtriyo?

The most commonly reported adverse effects, broken out by age group:

1. Children (6-12): rash, decreased appetite
2. Adolescents (13-17): decreased appetite, nausea, rash, headache, abdominal pain
3. Adults: headache, decreased appetite, insomnia, nausea, dry mouth, diarrhea

Nothing on that list is unusual for an ADHD medication. It’s a milder, more scattered profile than what stimulants typically produce — no widespread reports of appetite suppression severe enough to derail growth, no rebound crash pattern that shows up in the trial data.

There’s one warning that deserves more attention than the side effect bullet points get, though: the label notes higher rates of suicidal ideation and behavior in Simtriyo-treated patients aged 6-12 compared to placebo. That’s not a side note. If your kid is starting this, that’s a conversation to have with the prescriber directly, not something to skim past because the appetite and rash bullets read as manageable.

The Abuse Potential Story Got More Complicated

Back in March, we wrote that centanafadine’s trials showed no euphoria signal and might land in a less restrictive DEA schedule than stimulants. That’s still directionally true — the approved label reflects lower abuse potential in trial and non-clinical data compared to Schedule II stimulants.

But Simtriyo’s approved label also carries a boxed warning: potential for abuse and misuse, with abuse of CNS stimulants able to lead to substance use disorder, including addiction. That’s the FDA’s standard warning language for the entire CNS stimulant class, and it landed on Simtriyo’s label anyway — despite the no-euphoria trial data.

Worth being straight about that instead of just repeating the “safer than stimulants” pitch from earlier this year. The FDA’s caution here is a regulatory signal, not a contradiction of the trial data, but it means “lower abuse potential” and “no abuse potential” are not the same claim. Don’t let a marketing framing collapse that distinction for you.

The DEA Scheduling Holdup

Here’s the part that actually determines when you can fill a prescription: Simtriyo is FDA-approved but not yet legally prescribable. It still needs a controlled-substance schedule from the DEA before it reaches a pharmacy counter. Otsuka says it expects that to happen later in 2026, per the company’s approval announcement — but no firm date.

This isn’t a minor bureaucratic footnote. Where centanafadine lands matters commercially and practically. According to BioSpace’s coverage, Jefferies analysts pegged Otsuka’s own peak sales forecast for Simtriyo at more than $615 million, in what they called a large, under-penetrated ADHD market — and they flagged DEA scheduling as the variable that determines whether Simtriyo can actually differentiate itself. A Schedule II designation, the same tier as Adderall and Vyvanse, comes with prescribing restrictions (no refills, 30-day fill limits, prescriber and pharmacy friction) that would blunt the “easier access than stimulants” appeal. A lower schedule keeps that appeal intact.

In other words: the pharmacology story is settled. The access story isn’t.

Simtriyo Isn’t the Only New Approval This Year

Zoom out and 2026 has been an unusually active year for new ADHD medications. CTx-1301, Cingulate’s three-core timed-release dexmethylphenidate tablet, went through its own FDA decision in May — a stimulant reformulation rather than a new compound, built to close the afternoon coverage gap that XR stimulants leave behind.

Simtriyo and CTx-1301 are solving different problems for different people. CTx-1301 is for people whose current stimulant works but runs out of coverage before the day does. Simtriyo is for people who can’t or won’t take a stimulant at all — because of anxiety, abuse history, cardiac concerns, or just not wanting a Schedule II drug in the house. If your issue is coverage timing, watch CTx-1301. If your issue is the entire stimulant category, Simtriyo is the one that matters.

There’s also a slower-moving conversation this connects to: the ASCP’s first-ever consensus guidance on when to stop ADHD stimulants, published in May, names “associated harm” — anxiety worsening, emotional dysregulation, comorbid conditions getting worse on a stimulant — as a legitimate clinical reason to deprescribe. Simtriyo’s serotonin mechanism is exactly the kind of alternative that consensus implicitly points toward for people in that category. Worth raising with a prescriber together, once Simtriyo actually reaches a pharmacy.

What This Means If You’re Watching This Space

If you’re already medicated and it’s working, this changes nothing today. Simtriyo isn’t available. There’s no prescription to switch to yet, and won’t be for at least a few months.

If you’ve been holding off on a prescriber conversation until “it’s official,” it’s official now — but don’t expect them to have a prescribing pathway yet. Prescribers can start thinking about candidacy. They can’t write the script. The medication shortage that’s made stimulant access unreliable for years is exactly the backdrop that makes people want to jump on new options fast — worth remembering that “approved” and “obtainable” are different milestones here.

If the boxed warning changes your risk calculus, that’s a legitimate reason to wait and watch, not a reason to write the drug off entirely. New medications get real-world data over their first year or two on the market that trial data alone can’t fully predict. If you’re the type who prefers not to be an early adopter on anything with a fresh label, sitting this one out for six months to a year isn’t overcautious.

Keep the reminder habit going. DEA scheduling timelines shift. Pill reminder apps aren’t just for dosing — the calendar-alert function is exactly what catches a scheduling update that would otherwise vanish into a notification pile.

The Bottom Line

Simtriyo is approved. That part of the story is done, and it’s a real milestone — the first new ADHD medication class in twenty years actually cleared the FDA instead of stalling at priority review.

What’s not done: DEA scheduling, pharmacy availability, insurance formulary decisions, and — now that we have the actual label instead of trial-phase framing — a slightly messier abuse-potential story than “no euphoria in trials” alone suggested. The mechanism is genuinely new. The safety label is genuinely standard CNS-stimulant caution, boxed warning included. Both things are true at once.

If you were waiting for July 24 as the finish line, it wasn’t. It’s a checkpoint. The next one is whatever the DEA decides, and there’s no published date for that yet — so this is exactly the kind of update we’ll be watching for you.

---

Never start, stop, or switch ADHD medication without talking to your prescriber. This post reflects publicly available information as of August 7, 2026, and DEA scheduling timelines can shift without notice.